Research ArticleSpondyloarthritis

Effect of Gut Involvement in Patients with High Probability of Early Spondyloarthritis: Data from the DESIR Cohort

Daniel Wendling, Xavier Guillot, Clément Prati, Corinne Miceli-Richard, Anna Molto, Rik Lories and Maxime Dougados
The Journal of Rheumatology March 2020, 47 (3) 349-353; DOI: https://doi.org/10.3899/jrheum.181326

REFERENCES

  1. 1.↵
    1. Wendling D
    . The gut in spondyloarthritis. Joint Bone Spine 2016;83:401–5.
    OpenUrl
  2. 2.↵
    1. Rudwaleit M,
    2. Baeten D
    . Ankylosing spondylitis and bowel disease. Best Pract Res Clin Rheumatol 2006;20:451–71.
    OpenUrlCrossRefPubMed
  3. 3.↵
    1. Brakenhoff LK,
    2. van der Heijde DM,
    3. Hommes DW,
    4. Huizinga TW,
    5. Fidder HH
    . The joint-gut axis in inflammatory bowel diseases. J Crohns Colitis 2010;4:257–68.
    OpenUrlCrossRefPubMed
  4. 4.↵
    1. Van Praet L,
    2. Van den Bosch FE,
    3. Jacques P,
    4. Carron P,
    5. Jans L,
    6. Colman R,
    7. et al.
    Microscopic gut inflammation in axial spondyloarthritis: a multiparametric predictive model. Ann Rheum Dis 2013;72:414–7.
    OpenUrlAbstract/FREE Full Text
  5. 5.↵
    1. Van Praet L,
    2. Jans L,
    3. Carron P,
    4. Jacques P,
    5. Glorieus E,
    6. Colman R,
    7. et al.
    Degree of bone marrow oedema in sacroiliac joints of patients with axial spondyloarthritis is linked to gut inflammation and male sex: results from the GIANT cohort. Ann Rheum Dis 2014;73:1186–9.
    OpenUrlAbstract/FREE Full Text
  6. 6.↵
    1. Turina MC,
    2. Sieper J,
    3. Yeremenko N,
    4. Conrad K,
    5. Haibel H,
    6. Rudwaleit M,
    7. et al.
    Calprotectin serum level is an independent marker for radiographic spinal progression in axial spondyloarthritis. Ann Rheum Dis 2014;73:1746–8.
    OpenUrlFREE Full Text
  7. 7.↵
    1. Wendling D,
    2. Guillot X,
    3. Prati C
    . The IL-23/Th 17 pathway in spondyloarthritis: the royal road? Joint Bone Spine 2015;82:1–4.
    OpenUrlCrossRefPubMed
  8. 8.↵
    1. Ciccia F,
    2. Bombardieri M,
    3. Principato A,
    4. Giardina A,
    5. Tripodo C,
    6. Porcasi R,
    7. et al.
    Overexpression of interleukin-23, but not interleukin-17, as an immunologic signature of subclinical intestinal inflammation in ankylosing spondylitis. Arthritis Rheum 2009;60:955–65.
    OpenUrlCrossRefPubMed
  9. 9.↵
    1. Ciccia F,
    2. Accardo-Palumbo A,
    3. Rizzo A,
    4. Guggino G,
    5. Raimondo S,
    6. Giardina A,
    7. et al.
    Evidence that autophagy, but not the unfolded protein response, regulates the expression of IL-23 in the gut of patients with ankylosing spondylitis and subclinical gut inflammation. Ann Rheum Dis 2014;73:1566–74.
    OpenUrlAbstract/FREE Full Text
  10. 10.↵
    1. Ciccia F,
    2. Guggino G,
    3. Rizzo A,
    4. Saieva L,
    5. Peralta S,
    6. Giardina A,
    7. et al.
    Type 3 innate lymphoid cells producing IL-17 and IL-22 are expanded in the gut, in the peripheral blood, synovial fluid and bone marrow of patients with ankylosing spondylitis. Ann Rheum Dis 2015;74:1739–47.
    OpenUrlAbstract/FREE Full Text
  11. 11.↵
    1. Gill T,
    2. Asquith M,
    3. Rosenbaum JT,
    4. Colbert RA
    . The intestinal microbiome in spondyloarthritis. Curr Opin Rheumatol 2015;27:319–25.
    OpenUrlCrossRefPubMed
  12. 12.↵
    1. Dougados M,
    2. Etcheto A,
    3. Molto A,
    4. Alonso S,
    5. Bouvet S,
    6. Daurès JP,
    7. et al;
    8. DESIR cohort
    . Clinical presentation of patients suffering from recent onset chronic inflammatory back pain suggestive of spondyloarthritis: the DESIR cohort. Joint Bone Spine 2015;82:345–51.
    OpenUrlCrossRefPubMed
  13. 13.↵
    1. Stolwijk C,
    2. Essers I,
    3. van Tubergen A,
    4. Boonen A,
    5. Bazelier MT,
    6. De Bruin ML,
    7. et al.
    The epidemiology of extra-articular manifestations in ankylosing spondylitis: a population-based matched cohort study. Ann Rheum Dis 2015;74:1373–8.
    OpenUrlAbstract/FREE Full Text
  14. 14.↵
    1. Essers I,
    2. Ramiro S,
    3. Stolwijk C,
    4. Blaauw M,
    5. Landewé R,
    6. van der Heijde D,
    7. et al.
    Characteristics associated with the presence and development of extra-articular manifestations in ankylosing spondylitis: 12-year results from OASIS. Rheumatology 2015;54:633–40.
    OpenUrlCrossRefPubMed
  15. 15.↵
    1. Molodecky NA,
    2. Soon IS,
    3. Rabi DM,
    4. Ghali WA,
    5. Ferris M,
    6. Chernoff G,
    7. et al.
    Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology 2012;142:46–54.e42.
    OpenUrlCrossRefPubMed
  16. 16.↵
    1. Kirchgesner J,
    2. Lemaitre M,
    3. Rudnichi A,
    4. Racine A,
    5. Zureik M,
    6. Carbonnel F,
    7. et al.
    Therapeutic management of inflammatory bowel disease in real-life practice in the current era of anti-TNF agents: analysis of the French administrative health databases 2009–2014. Aliment Pharmacol Ther 2017;45:37–49.
    OpenUrl
  17. 17.↵
    1. Karreman MC,
    2. Luime JJ,
    3. Hazes JM,
    4. Weel AE
    . The prevalence and incidence of axial and peripheral spondyloarthritis in inflammatory bowel disease: a systematic review and meta-analysis. J Crohns Colitis 2017;11:631–42.
    OpenUrl
  18. 18.↵
    1. Essers I,
    2. Ramiro S,
    3. Stolwijk C,
    4. Blaauw M,
    5. Landewé R,
    6. van der Heijde D,
    7. et al.
    Do extra-articular manifestations influence outcome in ankylosing spondylitis? 12-year results from OASIS. Clin Exp Rheumatol 2016;34:214–21.
    OpenUrl
  19. 19.↵
    1. Resende GG,
    2. Lanna CC,
    3. Bortoluzzo AB,
    4. Gonçalves CR,
    5. da Silva JA,
    6. Ximenes AC,
    7. et al.
    Enteropathic arthritis in Brazil: data from the Brazilian Registry of Spondyloarthritis. Rev Bras Reumatol 2013;53:452–9.
    OpenUrl
  20. 20.↵
    1. de Winter JJ,
    2. van Mens LJ,
    3. van der Heijde D,
    4. Landewé R,
    5. Baeten DL
    . Prevalence of peripheral and extra-articular disease in ankylosing spondylitis versus non-radiographic axial spondyloarthritis: a meta-analysis. Arthritis Res Ther 2016;18:196.
    OpenUrl
  21. 21.↵
    1. Cantini F,
    2. Niccoli L,
    3. Nannini C,
    4. Cassarà E,
    5. Kaloudi O,
    6. Rizzello F,
    7. et al.
    Case-control study on dactylitis, enthesitis, and anterior uveitis in spondyloarthritis associated with inflammatory bowel diseases: role of coexistent psoriasis. J Rheumatol 2017;44:1341–6.
    OpenUrlAbstract/FREE Full Text
  22. 22.↵
    1. Colombo E,
    2. Latiano A,
    3. Palmieri O,
    4. Bossa F,
    5. Andriulli A,
    6. Annese V
    . Enteropathic spondyloarthropathy: a common genetic background with inflammatory bowel disease? World J Gastroenterol 2009;15:2456–62.
    OpenUrlCrossRefPubMed
  23. 23.↵
    1. Frei SM,
    2. Hemsley C,
    3. Pesch T,
    4. Lang S,
    5. Weber A,
    6. Jehle E,
    7. et al.
    The role for dickkopf-homolog-1 in the pathogenesis of Crohn’s disease-associated fistulae. PLoS One 2013;8:e78882.
    OpenUrlCrossRefPubMed
Back to top

In this issue

Print
Download PDF
Article Alerts
Email Article
Citation Tools

 Request Permissions

Bookmark this article

Jump to section

Keywords

SPONDYLOARTHRITIS
INFLAMMATORY BOWEL DISEASE
GASTROINTESTINAL DISEASES
EPIDEMIOLOGY

Keywords